KP - Pentamed® - High performance packaging films for medical devices

Opteev Unveils Breakthrough Multiplex Biochip: Rapidly Identifies COVID, Flu, RSV, and Respiratory Pathogens in Less Than 1 Minute

Opteev Technologies, a trailblazing company in the field of diagnostics, has recently submitted a patent application (Patent Application #63/513,007) showcasing a groundbreaking multiplex biochip tailored specifically for diagnosing respiratory infections. Crafted using state-of-the-art polymer materials, this inventive biochip holds the potential to rapidly test a diverse array of pathogens known to cause respiratory infections, including SARS-CoV-2, RSV, and Influenza. Impressively, this biochip's innovative design allows for the precise identification of the specific virus or bacteria in less than 60 seconds.

This advancement represents a significant milestone in diagnostics, introducing a portable, efficient, and dependable syndromic diagnostic tool that equips healthcare providers with instantaneous results. Operating in real-time, the compact biochip is capable of directly detecting entire viruses, boasting an exceptional success rate of 99.49% as demonstrated in analytical performance evaluations. Its accuracy is further heightened by the strategic selection of virus-binding peptides, ensuring the reliable identification of target viruses even within complex samples.

To enhance precision, artificial intelligence plays a pivotal role by optimizing frequency ranges and effectively mitigating any potential interference from noise signals. Unlike conventional respiratory panels that are both time-consuming and costly, Opteev's multiplex biochip disrupts this paradigm. It offers an affordable syndromic testing solution that can be administered at the point of care, enabling instantaneous and simultaneous detection and identification of multiple pathogens.

This technological advancement eliminates uncertainty, granting healthcare providers the essential insights needed to make precise and informed treatment decisions at the point of care. Beyond diagnostics, the transformative potential of this innovation extends to reshaping patient care approaches, streamlining operational processes, and introducing notable cost efficiencies.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CMO SummitHealthcare CNO Summit